德琪医药-B(6996.HK)：全新临床数据公布，管线价值加速释放

港股那点事2023-08-25

德琪医药（6996.HK）高差异化全球管线的临床开发正顺利推进，多项临床试验已取得积极的初步数据，希维奥®的商业化预期将继续看好。已有数据显示，除多发性骨髓瘤和弥漫性大B细胞淋巴瘤之外，希维奥®（塞利尼索）还具有相当大的适应症扩展潜力，目前共计7项临床试验正在开展，覆盖6个适应症。中后期临床资产ATG-008 （mTORC1/2抑制剂）在治疗宫颈癌方面持续在扩大的患者群中展现出极具前景及强有力的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2362293389?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-08-25 18:44","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2362293389","market":"hk","top_or_hot":-1,"title":"德琪医药-B(6996.HK)：全新临床数据公布，管线价值加速释放","media":"港股那点事","content":"<div>\n<p>德琪医药（6996.HK）高差异化全球管线的临床开发正顺利推进，多项临床试验已取得积极的初步数据，希维奥®的商业化预期将继续看好。已有数据显示，除多发性骨髓瘤和弥漫性大B细胞淋巴瘤之外，希维奥®（塞利尼索）还具有相当大的适应症扩展潜力，目前共计7项临床试验正在开展，覆盖6个适应症。中后期临床资产ATG-008 （mTORC1/2抑制剂）在治疗宫颈癌方面持续在扩大的患者群中展现出极具前景及强有力的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imzimkcz5393013.shtml\">网页链接</a>\n\n</div>\n","source":"highlight_sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪医药-B(6996.HK)：全新临床数据公布，管线价值加速释放</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪医药-B(6996.HK)：全新临床数据公布，管线价值加速释放\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-25 18:44 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imzimkcz5393013.shtml><strong>港股那点事</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>德琪医药（6996.HK）高差异化全球管线的临床开发正顺利推进，多项临床试验已取得积极的初步数据，希维奥®的商业化预期将继续看好。已有数据显示，除多发性骨髓瘤和弥漫性大B细胞淋巴瘤之外，希维奥®（塞利尼索）还具有相当大的适应症扩展潜力，目前共计7项临床试验正在开展，覆盖6个适应症。中后期临床资产ATG-008 （mTORC1/2抑制剂）在治疗宫颈癌方面持续在扩大的患者群中展现出极具前景及强有力的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imzimkcz5393013.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imzimkcz5393013.shtml","article_id":"2362293389","we_media_id":null,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imzimkcz5393013.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2362293389","pubTimestamp":1692960271,"sourceInfo":{"source_id":"highlight_sina","name":"新浪港股"},"weMediaInfo":null,"summary":"德琪医药高差异化全球管线的临床开发正顺利推进，多项临床试验已取得积极的初步数据，希维奥的商业化预期将继续看好。中后期临床资产ATG-008 在治疗宫颈癌方面持续在扩大的患者群中展现出极具前景及强有力的治疗潜力，德琪医药将在11月举行的年度研发日上公布该研究的最新数据。最新研究进展显示，ATG-101即将达到具有良好耐受性的生物有效剂量，并已经在低剂量组出现PR和持续的疾病稳定。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","06996":"德琪医药-B","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"Deqi Medicine-B (6996. HK): New clinical data is released, and pipeline value is accelerated","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"德琪医药（6996.HK）高差异化全球管线的临床开发正顺利推进，多项临床试验已取得积极的初步数据，希维奥®的商业化预期将继续看好。已有数据显示，除多发性骨髓瘤和弥漫性大B细胞淋巴瘤之外，希维奥®（塞利尼索）还具有相当大的适应症扩展潜力，目前共计7项临床试验正在开展，覆盖6个适应症。中后期临床资产ATG-008 （mTORC1/2抑制剂）在治疗宫颈癌方面持续在扩大的患者群中展现出极具前景及强有力的治疗潜力，德琪医药将在11月举行的年度研发日上公布该研究的最新数据。不仅如此，多个全球资产也取得显著进展，ATG-022（Claudin 18.2 抗体偶联药物）和ATG-101（PD-L1/4-1BB 双特异性抗体）这两项临床阶段资产，尽管还处于剂量探索阶段，都已在研究中心观察到部分缓解（PR）。最新研究进展显示，ATG-101即将达到具有良好耐受性的生物有效剂量，并已经在低剂量组出现PR和持续的疾病稳定（SD）。 \n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2362293389"}